Communiqués Lexaria Bioscience Corp.

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
2,78 ^USD	+5,70%		+3,35%	+122,40%

18/06	Lexaria Bioscience engage un organisme de recherche sous contrat pour une étude de 12 semaines	MT
18/06	Lexaria accorde un contrat à un ORC pour l'étude chronique de 12 semaines sur le GLP-1 de DehydraTECH chez l'humain	CI

Lexaria Awards CRO Contract For 12-Week DehydraTECH GLP-1 Chronic Human Study	18/06	AQ
Lexaria Bioscience : Corporate Presentation	06/06	PU
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	05/06	AQ
Lexaria Awards Contract For Third GLP-1 Human Pilot Study	23/05	AQ
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy	21/05	AQ
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study	17/05	AQ
Lexaria Begins Dosing of its Second GLP-1 Human Pilot Study	08/05	AQ
Lexaria Bioscience : Corporate Presentation	06/05	PU
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance	30/04	AQ
Lexaria Bioscience : Private Placement - Form 8-K	30/04	PU
Lexaria Bioscience : Corporate Highlight Sheet	11/04	PU
Lexaria Awarded New Patents	02/04	AQ
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K	21/03	PU
Lexaria to Present at The LD Micro Invitational XIV	21/03	NE
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	14/03	AQ
Lexaria Bioscience : Corporate Highlight Sheet	08/03	PU
Lexaria Awards Contract For Next GLP-1 Human Pilot Study	07/03	AQ
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1	05/03	AQ
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study	04/03	AQ
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	01/03	AQ

Aucun résultat pour cette recherche